Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 7.1% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company focused on developing CRISPR-based gene editing therapies for various genetic disorders. Today, NTLA experienced a significant bearish movement in the stock market.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 7.1% on Jun 2, 2026 18:26

• The bearish movement in NTLA's stock price today could be attributed to profit-taking by investors after a recent surge in the stock following positive Phase III trial results for its CRISPR-based therapy, lonvoguran ziclumeran.
• Despite the successful pivotal trial results for NTLA-2001 in treating ATTR amyloidosis with cardiomyopathy, the market may have reacted negatively due to concerns about the company's ongoing need for equity offerings to fund development, indicating potential dilution for existing shareholders.
• The undervaluation of NTLA highlighted by analysts, despite positive developments, might have also contributed to the bearish sentiment as investors may be cautious about the company's ability to secure strong payer support for expensive gene editing treatments in the future.
• Overall, the market movement in NTLA today reflects a mix of profit-taking, concerns about funding strategies, and uncertainties surrounding the commercialization and market acceptance of its CRISPR-based therapies.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

A Look At Intellia Therapeutics (NTLA) Valuation As Phase 3 HAELO Gene Editing Data Approaches

Intellia Therapeutics (NTLA) is drawing attention as it approaches the release of Phase 3 HAELO trial data for its gene editing therapy, lonvo-z, in hereditary angioedema. Despite significant short-term stock gains, analysts currently view NTLA as undervalued, citing a fair value of $26.70 against its current price of $13.73. However, this positive outlook is contingent on clean safety signals and strong payer support for expensive gene editing treatments, with current P/S ratios significantly higher than industry averages.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/a-look-at-intellia-therapeutics-ntla-valuation-as-phase-3-ha

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia Therapeutics will present additional Phase 3 HAELO clinical trial data for its CRISPR-based gene editing therapy, lonvo-z (formerly NTLA-2002), in hereditary angioedema (HAE) at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026. The presentation will detail results from the global, randomized, double-blind, placebo-controlled study, alongside a poster presentation on barriers to normalization with existing treatments for HAE patients in Europe. Lonvo-z aims to be a one-time treatment for HAE by permanently lowering kallikrein levels.

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-report-additional-phase-3-haelo-data

Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial

Intellia Therapeutics announced that its CRISPR-based treatment, NTLA-2001, met the primary endpoint in a pivotal Phase 3 trial for ATTR amyloidosis with cardiomyopathy. The trial demonstrated a statistically significant reduction in all-cause mortality and cardiovascular events compared to placebo. This success positions NTLA-2001 as a potential one-time gene editing therapy for the life-threatening condition.

http://www.msn.com/tr-tr/saglik/other/intellia-therapeutics-says-its-crispr-based-treatment-succeeds-in-pivotal-trial/ar-AA21OMw5?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift

Intellia Therapeutics (NTLA) shares rose 10.6% following positive Phase III results for its CRISPR therapy, lonvoguran ziclumeran, and the FDA lifting clinical holds on another candidate, nexiguran ziclumeran. These developments advance the company's in vivo CRISPR programs toward potential commercialization and reduce clinical and regulatory uncertainty. Despite these milestones, the company continues to fund development through equity offerings, highlighting the importance of timely FDA approvals and ongoing clinical success to mitigate cash burn.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-up-106-after-crispr-phase

Trending Today

Cardano ($ADA) Crypto Forecast: Down 7.6% Today

Bitcoin ($BTC) Crypto Forecast: Down 5.2% Today

QTUM ($QTUM) Crypto Forecast: Down 6.4% Today

Ethereum ($ETH) Crypto Forecast: Down 7.1% Today

Tractor Supply Company ($TSCO) Stock Forecast: Down 5.4% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Up 5.2% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.3% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 5.0% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Up 6.4% Today

Shopify Inc. Class A Subordinate ($SHOP) Stock Forecast: Down 5.9% Today

Intellia Therapeutics, Inc. Price History

01.05.2026 - NTLA Stock was up 5.4%

• NTLA-2001, Intellia's CRISPR-based treatment for ATTR amyloidosis with cardiomyopathy, successfully met the primary endpoint in a pivotal Phase 3 trial. This positive outcome, showing a significant reduction in mortality and cardiovascular events, has fueled investor optimism and confidence in the company's gene editing therapies.
• The FDA lifting clinical holds on Intellia's candidates, lonvoguran ziclumeran and nexiguran ziclumeran, further contributed to the stock's surge. These regulatory advancements signal progress towards potential commercialization and alleviate uncertainties surrounding the company's in vivo CRISPR programs.
• Despite the positive developments, the need for ongoing clinical success and timely FDA approvals to manage cash burn was highlighted by the company's reliance on equity offerings for funding. This underscores the importance of continued regulatory milestones and successful trial outcomes for sustaining investor interest and financial stability in the future.

18.04.2026 - NTLA Stock was down 5.7%

• The recent bearish movement in NTLA stock could be linked to negative insider sentiment, with an increase in share sales by corporate insiders over the past quarter, as noted by a Hold rating and $12.00 price target.
• Despite positive Phase 3 results for lonvo-z and progress on its biologics license application, mixed short-term share price performance and diverse views from analysts may have contributed to the downward pressure on the stock.
• The wide spread in analyst valuations, hinting at uncertainty about the company's growth potential, could have also influenced investors to take a cautious stance, resulting in the bearish movement in NTLA stock.
• In general, while the company's clinical advancements and financial strategy are respected, lingering concerns about valuation and differing views on future growth prospects appear to have impacted the stock performance.

14.04.2026 - NTLA Stock was down 9.8%

• Despite a reduced loss per share in Q1 2026, Intellia Therapeutics (NTLA) witnessed a decline in the market today.
• The company outperformed in earnings but fell short of revenue expectations, potentially influencing negative investor reactions.
• Analysts hold varying perspectives on the company's future, citing worries about sustained losses and the path to profitability that could have impacted the stock price.
• Negative insider sentiment and larger-than-anticipated losses per share in the recent quarter may have contributed to the stock's downturn, notwithstanding optimistic pipeline developments.

14.04.2026 - NTLA Stock was down 5.8%

• NTLA posted a Q1 2026 net loss of $96.2 million, which has sparked worries about its path to profitability and prompted a cautious response from investors.
• While exceeding earnings per share projections, the company fell short on revenue, reporting $15 million, leading to a downward trend in the market.
• The persistent losses, high price-to-sales ratio, and risks of dilution may have contributed to the prevailing bearish sentiment and decline in NTLA shares.
• Despite positive developments in its pipeline, such as successful Phase 3 outcomes for lonvo-z and the lifting of FDA clinical holds for nex-z trials, concerns about financial performance and short-term profitability seem to overshadow these advancements.

19.04.2026 - NTLA Stock was down 8.3%

• The recent bearish movement in NTLA's stock may be linked to investor concerns about potential dilution following a recent $180 million equity offering, despite an improved net loss reported in Q1 2026.
• Investors are wary of the possibility of further dilution if current cash burn rates persist, despite Intellia Therapeutics' affirmation of a multi-year cash runway and positive developments in its gene-editing pipeline.
• Market sentiment seems influenced by uncertainties surrounding future funding requirements and the trade-off between benefits from capital raising and risks of dilution, as suggested in recent discussions on the company's valuation and financial performance.
• Despite encouraging results from clinical trials and advancements in regulatory milestones, today's downward movement in the stock price may reflect a broader market reassessment of Intellia Therapeutics' growth prospects and valuation, resulting in a temporary decline in share value.

13.04.2026 - NTLA Stock was up 5.4%

• Despite reporting a significant Q1 loss, Intellia Therapeutics (NTLA) experienced a strong bullish movement in the stock market.
• The bullish movement can be attributed to the company's positive Phase 3 results for lonvo-z in hereditary angioedema (HAE) and the initiation of a rolling BLA submission for a potential U.S. launch in early 2027.
• Investors seem optimistic about Intellia's pipeline progress, including the lifting of FDA clinical holds for nex-z trials in ATTR amyloidosis, which indicates a promising future for the company's gene-editing programs.
• The market may also be reacting positively to Intellia's strategic reductions in R&D spending to focus on lead programs and commercial readiness, signaling a more efficient use of resources for future growth.

02.05.2026 - NTLA Stock was down 5.3%

• The bearish movement in NTLA stock could be attributed to profit-taking by investors after a recent bullish run following positive Phase III results for lonvoguran ziclumeran and the successful pivotal trial for NTLA-2001.
• Despite the positive news, investors may have been concerned about the company's reliance on equity offerings to fund development, leading to a cautious sentiment in the market.
• The market may also be reacting to potential uncertainties surrounding the commercialization timeline of Intellia's CRISPR therapies, as regulatory approvals and clinical success remain crucial factors for the company's growth trajectory.

02.05.2026 - NTLA Stock was down 7.1%

• The bearish movement in NTLA's stock price today could be attributed to profit-taking by investors after a recent surge in the stock following positive Phase III trial results for its CRISPR-based therapy, lonvoguran ziclumeran.
• Despite the successful pivotal trial results for NTLA-2001 in treating ATTR amyloidosis with cardiomyopathy, the market may have reacted negatively due to concerns about the company's ongoing need for equity offerings to fund development, indicating potential dilution for existing shareholders.
• The undervaluation of NTLA highlighted by analysts, despite positive developments, might have also contributed to the bearish sentiment as investors may be cautious about the company's ability to secure strong payer support for expensive gene editing treatments in the future.
• Overall, the market movement in NTLA today reflects a mix of profit-taking, concerns about funding strategies, and uncertainties surrounding the commercialization and market acceptance of its CRISPR-based therapies.

27.04.2026 - NTLA Stock was up 8.2%

• NTLA reported a reduced first-quarter loss, demonstrating improved financial performance compared to the prior year. This improvement has likely contributed to the positive movement in the stock.
• Positive Phase 3 clinical data for lonvo-z in Hereditary Angioedema (HAE) and advancements in other trials have enhanced investor confidence in the company's future prospects, leading to increased interest and a favorable market sentiment.
• Analysts have set a fair value target of $26.70 for the company, suggesting potential undervaluation. This, along with the anticipation of new product launches and a strengthened financial position, likely plays a role in the stock's upward momentum.
• The resolution of the patent infringement lawsuit counterclaims signals the end of legal uncertainties, potentially eliminating a source of concern for investors and further supporting the stock's positive trajectory.

22.04.2026 - NTLA Stock was up 5.6%

• The dismissal of four counterclaims in the BlueAllele patent infringement lawsuit is seen as a positive development for Intellia Therapeutics, reducing legal uncertainties and potential financial liabilities.
• The submission of the CRISPR-based gene editing therapy, nex-z, poses a unique regulatory challenge for the FDA, highlighting the innovative nature of Intellia's technology and its potential market impact.
• Despite concerns about dilution from a recent equity offering, Intellia's improved net loss in Q1 2026 and emphasis on a multi-year cash runway are reassuring investors about the company's financial stability and ability to execute its gene-editing pipeline.
• Investor focus on Intellia's gene-editing pipeline progress, upcoming clinical trial readouts, and regulatory milestones underscores the market's anticipation of potential breakthroughs in the competitive gene-editing landscape, further boosting confidence in the company's growth prospects.

11.04.2026 - NTLA Stock was up 5.0%

• The bullish movement in NTLA's stock price can be attributed to the positive anticipation of beating earnings estimates, supported by a history of surpassing EPS estimates in previous quarters.
• The announcement of Intellia's participation in multiple investor conferences and fireside chats may have increased investor confidence in the company's strategic initiatives and future prospects.
• Cathie Wood's ARK Invest increasing its stake in NTLA could have also contributed to the bullish momentum, signaling confidence from a prominent investor in the biotech sector.
• Conflicting valuation metrics may have caused some volatility in the stock price, with investors potentially weighing the undervaluation suggested by the DCF model against the overvaluation indicated by the P/S ratio.

12.04.2026 - NTLA Stock was down 7.0%

• NTLA stock's decline might be linked to the company's Q1 2026 financial figures, indicating a net loss of $96.2 million and lower revenue compared to the previous year.
• Despite achieving Phase 3 milestones for lonvo-z and progressing its gene-editing projects, investors possibly worried about NTLA's financial performance and the recent stock offering for additional funding.
• The difference in valuation assessments, with the DCF model suggesting undervaluation and the P/S ratio hinting at overvaluation, may have contributed to investor uncertainty, influencing the bearish movement.
• Overall, investor sentiment towards NTLA appears guarded today, considering the promise of its gene editing treatments alongside the company's financial struggles and valuation ambiguity.